HansBiomed Corporation Asset Resilience Ratio
HansBiomed Corporation asset resilience ratio. HansBiomed Corporation (042520) has an Asset Resilience Ratio of 9.13% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HansBiomed Corporation defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of HansBiomed Corporation (2012–2023)
Asset resilience ratio of HansBiomed Corporation from 2012 to 2023. This chart shows how HansBiomed Corporation's Asset Resilience Ratio has changed over time. Read HansBiomed Corporation (042520) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down HansBiomed Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see HansBiomed Corporation total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩11.75 Billion | 9.13% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩11.75 Billion | 9.13% |
Asset Resilience Insights
- Limited Liquidity: HansBiomed Corporation maintains only 9.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
HansBiomed Corporation Industry Peers by Asset Resilience Ratio
Compare HansBiomed Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
HansBiomed Corporation Asset Resilience Ratio by Year (2012–2023)
HansBiomed Corporation asset resilience ratio by year from 2012 to 2023. The table below shows the annual Asset Resilience Ratio data for HansBiomed Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-09-30 | 0.75% | ₩916.26 Million ≈ $620.93K |
₩122.37 Billion ≈ $82.93 Million |
-10.63pp |
| 2022-09-30 | 11.38% | ₩14.98 Billion ≈ $10.15 Million |
₩131.69 Billion ≈ $89.24 Million |
-4.28pp |
| 2021-09-30 | 15.66% | ₩20.27 Billion ≈ $13.74 Million |
₩129.44 Billion ≈ $87.72 Million |
-2.22pp |
| 2020-09-30 | 17.88% | ₩23.57 Billion ≈ $15.97 Million |
₩131.81 Billion ≈ $89.32 Million |
+10.12pp |
| 2019-09-30 | 7.76% | ₩10.40 Billion ≈ $7.05 Million |
₩134.09 Billion ≈ $90.87 Million |
-1.68pp |
| 2018-09-30 | 9.44% | ₩8.66 Billion ≈ $5.87 Million |
₩91.80 Billion ≈ $62.21 Million |
+3.53pp |
| 2017-09-30 | 5.90% | ₩4.73 Billion ≈ $3.21 Million |
₩80.19 Billion ≈ $54.34 Million |
+2.61pp |
| 2016-09-30 | 3.29% | ₩2.13 Billion ≈ $1.44 Million |
₩64.72 Billion ≈ $43.86 Million |
+3.27pp |
| 2015-09-30 | 0.02% | ₩9.04 Million ≈ $6.13K |
₩52.11 Billion ≈ $35.32 Million |
-0.13pp |
| 2014-09-30 | 0.15% | ₩67.25 Million ≈ $45.58K |
₩44.34 Billion ≈ $30.05 Million |
-0.09pp |
| 2013-09-30 | 0.25% | ₩81.89 Million ≈ $55.50K |
₩33.36 Billion ≈ $22.61 Million |
-15.68pp |
| 2012-09-30 | 15.92% | ₩4.31 Billion ≈ $2.92 Million |
₩27.05 Billion ≈ $18.33 Million |
-- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more